Last reviewed 2026-04-19 · How we verify

Granuloma annulare

Approved treatments

• Flucorticin
• Aclovate
• Cordran · Aqua Pharms
• Cutivate · Teva Pharm
• Benzamycin · Mayne Pharma
• Topicort · Taro
• Derma-Smoothe/Fs · Eurofarma
• Cloderm · Legacy Pharma
• Cortone
• Ultravate · Ranbaxy
  Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation.
• Diprolene · Merck & Co.
  Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system.
• Verdeso · Padagis Us
• Betamethasone Valerate · Fougera Pharms Inc
• Decadron · Generic (originally Merck)
• Flonase · GSK (GlaxoSmithKline)
• Nasonex · University of Alberta
• Medrol · Generic (originally Upjohn/Pfizer)
  Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions.
• Betamethasone 17-Benzoate
• Cortef · Generic (originally Merck/Upjohn)
• Rodinolone
• Flixotide · Mundipharma Research Limited
• Fluticason · Creighton University
• Lidex
• Halog · Sun Pharma
• Lac-Hydrin · Sun Pharma
• Dermatop · Bausch Health
• Elocon · Merck & Co.
  Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body.
• Psorcon · Pfizer
• Cyclocort · Astellas Pharma
• Betametasone
  Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system.
• Cortisol · University of Zurich
• Prelone · Generic (originally Schering)
• Benoxyl · Aier School of Ophthalmology, Central South University
• prednisolon · Hannover Medical School
• Methylprednisolon · Leiden University Medical Center
• MOMETASONE
  12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Granuloma annulare patent landscape — cliff calendar, originator estates, attackable patents
• Granuloma annulare treatment landscape brief
• Granuloma annulare treatment updates RSS

Frequently asked questions about Granuloma annulare

Related

• Treatment landscape: Granuloma annulare patent cliff · Granuloma annulare CI report
• Treatment: Flucorticin
• Treatment: Aclovate
• Treatment: Cordran · Aqua Pharms
• Treatment: Cutivate · Teva Pharm
• Treatment: Benzamycin · Mayne Pharma
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing